Apex Biotechnology Corp.
1733
Rank in Stocks
#20350
Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global... Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.
Share Price
$0.86271018
Last synced: 2026-11-10
Market Cap
$86.23M
Change (1 day)
-1.57%
Change (1 year)
-16.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Apex Biotechnology Corp. (1733)
Category
Healthcare
Operating Margin for Apex Biotechnology Corp. (1733)
Operating Margin as of November 2026 TTM: 9.27%
According to Apex Biotechnology Corp.'s latest financial reports, its current operating margin (TTM) is 9.27%. At the end of 2025 the company had an operating margin of 7.24%.
Operating Margin history for Apex Biotechnology Corp. from 2009 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 9.27% | 28.04% |
| 2025 | 7.24% | 4.32% |
| 2024 | 6.94% | -17.87% |
| 2023 | 8.45% | -7.45% |
| 2022 | 9.13% | 0.33% |
| 2021 | 9.10% | 51.41% |
| 2020 | 6.01% | -23.54% |
| 2019 | 7.86% | -29.32% |
| 2018 | 11.12% | 23.97% |
| 2017 | 8.97% | -35.65% |
| 2016 | 13.94% | -14.37% |
| 2015 | 16.28% | 0.62% |
| 2014 | 16.18% | -15.20% |
| 2013 | 19.08% | -35.84% |
| 2012 | 29.74% | 0.07% |
| 2011 | 29.72% | -9.42% |
| 2010 | 32.81% | 5.03% |
| 2009 | 31.24% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -95.84% |
US
|
|
| -149.01% | -116.07% |
US
|
|
| 25.57% | -97.24% |
AU
|
|
| 31.23% | -96.63% |
BE
|
|
| 29.35% | -96.83% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Apex Biotechnology Corp.'s operating margin
What is Apex Biotechnology Corp.'s operating margin?
Apex Biotechnology Corp.'s operating margin is 9.27%, as of Nov 2026.
What was Apex Biotechnology Corp.'s operating margin in 2025?
In 2025, Apex Biotechnology Corp.'s operating margin was 7.24%, compared with 6.94% in 2024.
How has Apex Biotechnology Corp.'s operating margin changed since 2020?
From 2020 to 2025, Apex Biotechnology Corp.'s operating margin was highest in 2022 (9.13%) and lowest in 2020 (6.01%).
How does Apex Biotechnology Corp.'s operating margin compare with similar companies?
Apex Biotechnology Corp.'s operating margin (9.27%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.